Drug Interactions of Newer Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban with Routinely Used Nonanticoagulant/Antiplatelet Drugs

被引：0
|
作者：
Sayani, Shermin [1 ]
Iqbal, Omer [1 ]
Hoppensteadt, Debra [1 ]
Fareed, Jawed [1 ]
机构：
[1] Loyola Univ, Med Ctr, Maywood, IL 60153 USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 48 条
  • [11] Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development
    Ufer, Mike
    THROMBOSIS AND HAEMOSTASIS, 2010, 103 (03) : 572 - 585
  • [12] The frequency of potential drug interactions involving dabigatran, rivaroxaban, and apixaban in a veteran population
    Hassanzadah, Mehgan
    Crumpler, Walter
    Chan, Linh
    Jacobson, Alan
    Gogineni, Hyma
    Shankar, Gollapudi
    Chau, Tony
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2015, 39 (03) : 419 - 419
  • [13] Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban
    Steiner, T.
    Boehm, M.
    Dichgans, M.
    Diener, H. -C.
    Ell, C.
    Endres, M.
    Epple, C.
    Grond, M.
    Laufs, U.
    Nickenig, G.
    Riess, H.
    Roether, J.
    Schellinger, P. D.
    Spannagl, M.
    Veltkamp, R.
    CLINICAL RESEARCH IN CARDIOLOGY, 2013, 102 (06) : 399 - 412
  • [14] Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban
    T. Steiner
    M. Böhm
    M. Dichgans
    H.-C. Diener
    C. Ell
    M. Endres
    C. Epple
    M. Grond
    U. Laufs
    G. Nickenig
    H. Riess
    J. Röther
    P. D. Schellinger
    M. Spannagl
    R. Veltkamp
    Clinical Research in Cardiology, 2013, 102 : 399 - 412
  • [15] Perioperative complications with new oral anticoagulants dabigatran, apixaban, and rivaroxaban in Mohs micrographic surgery: A retrospective study
    Antia, Camila
    Hone, Natalie
    Gloster, Hugh
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 77 (05) : 967 - 968
  • [16] A HESI LC-MS/MS method for determination of direct oral anticoagulants (Apixaban, Rivaroxaban, Dabigatran)
    Montange, D.
    Le Poupon, J.
    Galmiche, A.
    Davani, S.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2015, 29 : 62 - 62
  • [17] New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) and Vitamin K Antagonists: Incidence and Treatment Patterns in 2012 in France
    Maura, G.
    Billionnet, C.
    Weill, A.
    Ricordeau, P.
    Alla, F.
    Allemand, H.
    DRUG SAFETY, 2013, 36 (09) : 836 - 836
  • [18] HOSPITAL READMISSIONS AMONG PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION TREATED WITH THE NEW ORAL ANTICOAGULANTS, APIXABAN, DABIGATRAN, AND RIVAROXABAN
    Deitelzweig, Steven
    Gupta, Kiran
    Nadkarni, Anagha
    Trocio, Jeffrey
    Lin, Jay
    Lingohr-Smith, Melissa
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 805 - 805
  • [19] Development of an UHPLC-UV-Method for Quantification of Direct Oral Anticoagulants: Apixaban, Rivaroxaban, Dabigatran, and its Prodrug Dabigatran Etexilate in Human Serum
    Boehr, Sebastian
    Haen, Ekkehard
    THERAPEUTIC DRUG MONITORING, 2017, 39 (01) : 66 - 76
  • [20] Assessment of the effect of direct oral anticoagulants dabigatran, rivaroxaban, and apixaban in healthy male volunteers using a thrombin generation assay
    Artang, Ramin
    Anderson, Maren
    Riley, Paul
    Nielsen, Jorn D.
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2017, 1 (02) : 194 - 201
12345